AgingResearch.NewsJoin free
medRxiv

Drugs linked to fewer deaths in obese statin users with artery disease

Over three years, deaths occurred in 4.0% of patients adding the drugs to statins versus 7.5% taking statins alone.

Paper by S. Tah, M. Cheshire · West Virginia University School of Medicine

Our read

Interventions
Studied:
Preprint: cohort study of 920,176 people (3 years)
In the record:
The 1,328th paper on GLP-1 receptor agonists with results in people; 4,609 on record in all. Its result on mortality agrees with 158 of 178 other findings on record; 1 points the other way and 19 found no change.
Why it’s aging research:
It studies an intervention with evidence of extending healthy life.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

Patients with obesity and atherosclerotic cardiovascular disease, which involves fatty buildup in arteries, were studied in an observational cohort using a US healthcare network of 108 organizations. All took statins, medicines that lower cholesterol. Researchers matched 119,911 pairs on 34 characteristics. They compared people starting glucagon-like peptide-1 receptor agonists, drugs that mimic a hormone involved in blood sugar control, with people taking statins alone.

Over three years, deaths occurred in 4.0% of the added-drug group and 7.5% of the statin-only group. Added-drug use was also associated with lower risks of heart attack and stroke caused by blocked blood flow. The authors suggested these drugs may offer added heart protection alongside statins in this population.

Why it matters

For age-related artery disease, the question is whether adding another medicine can offer protection beyond cholesterol control.

Caveats

People prescribed the added drugs may have differed in health or care in ways the matching did not capture. The report is a preprint, not yet peer-reviewed, and the findings concern people with obesity and established cardiovascular disease.

Comments

Be the first to comment.

More peptides

Related